Ignite Creation Date:
2025-12-24 @ 9:14 PM
Ignite Modification Date:
2026-05-30 @ 11:09 PM
Study NCT ID:
NCT05266404
Status:
COMPLETED
Last Update Posted:
2022-07-05
First Post:
2022-02-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components
Sponsor:
AstraZeneca
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus) | View |